FDA Approves Teva’s Weltruza: The First Once-Monthly Subcutaneous Olanzapine for Schizophrenia
FDA approved Teva’s Weltruza (olanzapine monthly injection) on October 9, 2026—the first once-monthly subcutaneous olanzapine for schizophrenia. SOLARIS trial: PANSS -11.27 pts. No loading dose, no monitoring required.